Sublingual Dexmedetomidine for Treating Opioid Withdrawal
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
Active, not recruiting · NCT05712707 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sublingual Dexmedetomidine for Treating Opioid Withdrawal | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-14 | NCT05712707 |
6 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioXcel Therapeutics Inc | 4 |
| CenExel HRI | 1 |
| Clinilabs, Inc. | 2 |
| National Institute on Drug Abuse (NIDA) | 549 |
| New York State Psychiatric Institute | 35 |
| Yale University | 458 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cenexel HRI | Marlton | United States | 2 |
| Clinilabs | Eatontown | United States | 2 |
| New York State Psychiatric Institute | New York | United States | 22 |
| Yale University | New Haven | United States | 29 |